Jazz Pharmaceuticals plc Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Jazz Pharmaceuticals plc (JAZZ) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$11.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-03
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$11.50M, a 103.83% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$82.40M, a 150.86% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $1.30M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$84.13M, a 129.54% decline year-over-year.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $379.07M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$105.52M, a 137.24% decline from fiscal 2023.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $283.36M.
- Jazz Pharmaceuticals plc other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$725.15M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.50M 10-Q · filed 2026-08-03 | -$93.90M 10-Q · filed 2026-08-03 | -$92.60M derived: sum of 3 quarters · filed 2026-08-03 | -$176.73M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | -$82.40M 10-Q · filed 2026-08-03 | -$81.10M derived: sum of 2 quarters · filed 2026-08-03 | -$165.23M derived: sum of 3 quarters · filed 2026-08-03 | $134.67M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$82.83M derived: sum of 2 quarters · filed 2026-02-24 | $217.07M derived: sum of 3 quarters · filed 2026-08-03 | $379.07M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | -$84.13M 10-Q · filed 2025-11-05 | $215.77M derived: sum of 2 quarters · filed 2026-08-03 | $377.77M 10-Q · filed 2025-11-05 | $33.50M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $299.90M 10-Q · filed 2026-08-03 | $299.84M 10-Q · filed 2025-08-06 | $461.90M 10-Q · filed 2026-08-03 | $461.90M 10-Q · filed 2025-08-06 | $117.63M derived: sum of 3 quarters · filed 2026-08-03 | $402.46M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $162.00M 10-Q · filed 2026-08-03 | $162.06M 10-Q · filed 2025-05-07 | -$182.27M derived: sum of 2 quarters · filed 2026-08-03 | $102.56M derived: sum of 3 quarters · filed 2026-08-03 | $96.73M derived: sum of 4 quarters · filed 2026-08-03 | |
| 2024-12-31 | -$344.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$59.44M derived: sum of 2 quarters · filed 2026-02-24 | -$65.27M derived: sum of 3 quarters · filed 2026-02-24 | -$105.52M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $284.83M 10-Q · filed 2025-11-05 | $279.00M derived: sum of 2 quarters · filed 2025-11-05 | $238.75M 10-Q · filed 2025-11-05 | $432.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | -$5.83M 10-Q · filed 2025-11-05 | -$46.08M 10-Q · filed 2025-08-06 | $147.17M derived: sum of 3 quarters · filed 2026-02-24 | -$21.40M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | -$40.25M 10-Q · filed 2025-11-05 | $153.00M derived: sum of 2 quarters · filed 2026-02-24 | -$15.57M derived: sum of 3 quarters · filed 2026-02-24 | $97.84M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $193.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $24.68M derived: sum of 2 quarters · filed 2026-02-24 | $138.08M derived: sum of 3 quarters · filed 2026-02-24 | $283.36M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | -$168.58M 10-Q · filed 2024-11-07 | -$55.17M derived: sum of 2 quarters · filed 2024-11-07 | $90.11M 10-Q · filed 2024-11-07 | $582.25M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $113.41M 10-Q · filed 2024-11-07 | $258.69M 10-Q · filed 2024-08-01 | $750.82M derived: sum of 3 quarters · filed 2025-02-26 | $239.21M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $145.28M 10-Q · filed 2024-11-07 | $637.42M derived: sum of 2 quarters · filed 2025-02-26 | $125.80M derived: sum of 3 quarters · filed 2025-02-26 | -$389.51M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $492.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$19.48M derived: sum of 2 quarters · filed 2025-02-26 | -$534.79M derived: sum of 3 quarters · filed 2025-02-26 | -$725.15M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | -$511.62M 10-Q · filed 2023-11-08 | -$1.03B derived: sum of 2 quarters · filed 2023-11-08 | -$1.22B 10-Q · filed 2023-11-08 | -$1.22B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | -$515.31M 10-Q · filed 2023-11-08 | -$705.67M 10-Q · filed 2023-08-09 | -$708.51M derived: sum of 3 quarters · filed 2024-02-28 | -$915.09M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | -$190.36M 10-Q · filed 2023-11-08 | -$193.20M derived: sum of 2 quarters · filed 2024-02-28 | -$399.79M derived: sum of 3 quarters · filed 2024-02-28 | -$411.29M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$209.43M derived: sum of 2 quarters · filed 2024-02-28 | -$220.93M derived: sum of 3 quarters · filed 2024-02-28 | -$266.01M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | -$206.58M 10-Q · filed 2022-11-09 | -$218.09M derived: sum of 2 quarters · filed 2022-11-09 | -$263.17M 10-Q · filed 2022-11-09 | -$209.72M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | -$11.51M 10-Q · filed 2022-11-09 | -$56.58M 10-Q · filed 2022-08-03 | -$3.13M derived: sum of 3 quarters · filed 2023-03-01 | $45.17M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | -$45.08M 10-Q · filed 2022-11-09 | $8.37M derived: sum of 2 quarters · filed 2023-03-01 | $56.68M derived: sum of 3 quarters · filed 2023-03-01 | $78.01M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $53.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $101.76M derived: sum of 2 quarters · filed 2023-03-01 | $123.08M derived: sum of 3 quarters · filed 2023-03-01 | $89.04M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $48.31M 10-Q · filed 2021-11-09 | $69.64M derived: sum of 2 quarters · filed 2021-11-09 | $35.59M 10-Q · filed 2021-11-09 | $71.64M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $21.33M 10-Q · filed 2021-11-09 | -$12.72M 10-Q · filed 2021-08-03 | $23.33M derived: sum of 3 quarters · filed 2022-03-01 | -$25.67M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | -$34.04M 10-Q · filed 2021-11-09 | $2.01M derived: sum of 2 quarters · filed 2022-03-01 | -$47.00M derived: sum of 3 quarters · filed 2022-03-01 | -$36.76M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $36.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$12.96M derived: sum of 2 quarters · filed 2022-03-01 | -$2.72M derived: sum of 3 quarters · filed 2022-03-01 | -$25.60M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$49.01M 10-Q · filed 2020-11-02 | -$38.77M derived: sum of 2 quarters · filed 2020-11-02 | -$61.65M 10-Q · filed 2020-11-02 | -$79.98M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-06-30 | $10.24M 10-Q · filed 2020-11-02 | -$12.64M 10-Q · filed 2020-08-04 | -$30.97M derived: sum of 3 quarters · filed 2021-02-23 | -$42.21M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-03-31 | -$22.88M 10-Q · filed 2020-11-02 | -$41.21M derived: sum of 2 quarters · filed 2021-02-23 | -$52.45M derived: sum of 3 quarters · filed 2021-02-23 | -$121.91M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2018-12-31 | -$18.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | -$29.56M derived: sum of 2 quarters · filed 2021-02-23 | -$99.02M derived: sum of 3 quarters · filed 2021-02-23 | -$56.97M 10-K · filed 2021-02-23 | ||
| 2018-09-30 | -$11.24M 10-Q · filed 2019-11-05 | -$80.70M derived: sum of 2 quarters · filed 2019-11-05 | -$38.64M 10-Q · filed 2019-11-05 | -$20.53M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | -$69.46M 10-Q · filed 2019-11-05 | -$27.40M 10-Q · filed 2019-08-06 | -$9.29M derived: sum of 3 quarters · filed 2020-02-25 | $41.97M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | $42.06M 10-Q · filed 2019-11-05 | $60.17M derived: sum of 2 quarters · filed 2020-02-25 | $111.43M derived: sum of 3 quarters · filed 2020-02-25 | $201.02M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $18.11M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $69.37M derived: sum of 2 quarters · filed 2020-02-25 | $158.97M derived: sum of 3 quarters · filed 2020-02-25 | $176.46M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $51.26M 10-Q · filed 2018-11-06 | $140.86M derived: sum of 2 quarters · filed 2018-11-06 | $158.35M 10-Q · filed 2018-11-06 | $76.39M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $89.59M 10-Q · filed 2018-08-07 | $107.08M 10-Q · filed 2018-08-07 | $25.13M derived: sum of 3 quarters · filed 2019-02-26 | $39.74M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $17.49M 10-Q · filed 2018-05-08 | -$64.47M derived: sum of 2 quarters · filed 2019-02-26 | -$49.85M derived: sum of 3 quarters · filed 2019-02-26 | -$77.56M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2016-12-31 | -$81.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$67.34M derived: sum of 2 quarters · filed 2019-02-26 | -$95.05M derived: sum of 3 quarters · filed 2019-02-26 | -$49.86M 10-K · filed 2019-02-26 | ||
| 2016-09-30 | $14.61M 10-Q · filed 2017-11-07 | -$13.09M derived: sum of 2 quarters · filed 2017-11-07 | $32.10M 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | -$27.70M 10-Q · filed 2017-08-08 | $17.48M 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | $45.19M 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |